M. Habibian and M. Dehghani, “Out-of-pocket costs analysis of ifosfamide, epirubicin, and etoposide (IEV) and etoposide, solu-medrol-methylprednisolone, high-dose ara-C-cytarabine, and platinol-cisplatin (ESHAP) regimens in the patients with relapsed and refractory lymphoma in Iran”, Chron Dis J, vol. 6, no. 2, pp. 87–92, Jun. 2018.